Revance Therapeutics (RVNC) Stock Statistics & Valuation Metrics

Revance Therapeutics has a market cap or net worth of $381.02M. The enterprise value is ―.

Revance Therapeutics has 104,389,885 shares outstanding. The number of shares has decreased by -2.65% in one year.

Revance Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Revance Therapeutics had revenue of 234.04M and earned -323.99M in profits. Earnings per share was -3.83.

In the last 12 months, operating cash flow was -190.89M and capital expenditures -4.02M, giving a free cash flow of -194.91M billion.

Revance Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Revance Therapeutics upcoming earnings date is ―, ―.

Revance Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Revance Therapeutics has paid 300.00K in taxes.

Revance Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Revance Therapeutics has $184.08M in cash and marketable securities with $483.45M in debt, giving a net cash position of $299.37M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Revance Therapeutics is $3.05, which is 11.43% higher than the current price. The consensus rating is Hold